• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (65)  • Contact me when this article is cited  Related Content  • Related letter  • Related articles  • Similar articles in this journal  Topic Collections  • Nutritional and Metabolic Disorders  • Nutritional and Metabolic Disorders, Other  • Cardiovascular System  • Quality of Care  • Evidence-Based Medicine  • Review  • Prognosis/ Outcomes  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Endocrine Diseases  • Diabetes Mellitus  • Alert me on articles by topic  Social Bookmarking   What's this?

An Updated Meta-analysis of Risk for Myocardial Infarction and Cardiovascular Mortality

Steven E. Nissen, MD; Kathy Wolski, MPH

Arch Intern Med. 2010;170(14):1191-1201. doi:10.1001/archinternmed.2010.207

Context  Controversy regarding the effects of rosiglitazone therapy on myocardial infarction (MI) and cardiovascular (CV) mortality persists 3 years after a meta-analysis initially raised concerns about the use of this drug.

Objective  To systematically review the effects of rosiglitazone therapy on MI and mortality (CV and all-cause).

Data Sources  We searched MEDLINE, the Web site of the Food and Drug Administration, and the GlaxoSmithKline clinical trials registry for trials published through February 2010.

Study Selection  The study included all randomized controlled trials of rosiglitazone at least 24 weeks in duration that reported CV adverse events.

Data Extraction  Odds ratios (ORs) for MI and mortality were estimated using a fixed-effects meta-analysis of 56 trials, which included 35 531 patients: 19 509 who received rosiglitazone and 16 022 who received control therapy.

Results  Rosiglitazone therapy significantly increased the risk of MI (OR, 1.28; 95% confidence interval [CI], 1.02-1.63; P = .04) but not CV mortality (OR, 1.03; 95% CI, 0.78-1.36; P = .86). Exclusion of the RECORD (Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes) trial yielded similar results but with more elevated estimates of the OR for MI (OR, 1.39; 95% CI, 1.02-1.89; P = .04) and CV mortality (OR, 1.46; 95% CI, 0.92-2.33; P = .11). An alternative analysis pooling trials according to allocation ratios allowed inclusion of studies with no events, yielding similar results for MI (OR, 1.28; 95% CI, 1.01-1.62; P = .04) and CV mortality (OR 0.99; 95% CI, 0.75-1.32; P = .96).

Conclusions  Eleven years after the introduction of rosiglitazone, the totality of randomized clinical trials continue to demonstrate increased risk for MI although not for CV or all-cause mortality. The current findings suggest an unfavorable benefit to risk ratio for rosiglitazone.

Author Affiliations: Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED LETTER

Analytical Issues Regarding Rosiglitazone Meta-analysis—Reply
Steven E. Nissen and Kathy Wolski
Arch Intern Med. 2011;171(2):180.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated With Rosiglitazone or Pioglitazone
David J. Graham, Rita Ouellet-Hellstrom, Thomas E. MaCurdy, Farzana Ali, Christopher Sholley, Christopher Worrall, and Jeffrey A. Kelman
JAMA. 2010;304(4):411-418.
ABSTRACT | FULL TEXT  

Rosiglitazone and the Case for Safety Over Certainty
David N. Juurlink
JAMA. 2010;304(4):469-471.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions
Bourg and Phillips
The Annals of Pharmacotherapy 2012;46:282-289.
ABSTRACT | FULL TEXT  

Alteration in myocardial prostaglandin D synthase expression in pressure overload-induced left ventricular remodeling in rats
Nagalla et al.
Exp Biol Med 2012;237:24-30.
ABSTRACT | FULL TEXT  

Chapter 4 Pharmacotherapy in type 2 diabetes: clinical evidence
Sreemantula et al.
ODL Type 2 Diabetes 2011;2:med-9780199596171-chapter-med-9780199596171-chapter.
ABSTRACT | FULL TEXT  

Chapter 5 Multiple cardiovascular risk intervention
Fisher
ODL Type 2 Diabetes 2011;2:med-9780199596171-chapter-med-9780199596171-chapter.
ABSTRACT | FULL TEXT  

Chapter 2 Hyperglycaemia and weight management
Fisher
Heart Disease and Diabetes 2011;2:med-9780199604562-chapter-med-9780199604562-chapter.
ABSTRACT | FULL TEXT  

The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance: application to diabetes and vascular disease
Blake et al.
British Journal of Diabetes & Vascular Disease 2011;11:304-307.
ABSTRACT  

The Seduction of Biomarkers in the Practice of Medicine and the Tyranny of Power in the Drug Approval Process: Lessons From Niacin
Lehmann and Sitar
J Clin Pharmacol 2011;51:1496-1498.
FULL TEXT  

Rosiglitazone and Pioglitazone for the Treatment of Alzheimer's Disease
Miller et al.
The Annals of Pharmacotherapy 2011;45:1416-1424.
ABSTRACT | FULL TEXT  

Secondary use of randomized controlled trials to evaluate drug safety: a review of methodological considerations
Hammad et al.
Clin Trials 2011;8:559-570.
ABSTRACT | FULL TEXT  

Thiazolidinedione insulin sensitizers alter lipid bilayer properties and voltage-dependent sodium channel function: implications for drug discovery
Rusinova et al.
JGP 2011;138:249-270.
ABSTRACT | FULL TEXT  

Patient-Centered Medicine: The Next Phase in Health Care
Krumholz
Circ Cardiovasc Qual Outcomes 2011;4:374-375.
FULL TEXT  

Rosiglitazone improves endothelial function in patients with type 2 diabetes treated with insulin
Naka et al.
Diabetes and Vascular Disease Research 2011;8:195-201.
ABSTRACT  

Assessing Cardiovascular Risk Factors and Selecting Agents to Successfully Treat Patients With Type 2 Diabetes Mellitus
Baldwin
J Am Osteopath Assoc 2011;111:S2-S12.
ABSTRACT | FULL TEXT  

Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations
Bennett et al.
ANN INTERN MED 2011;154:602-613.
ABSTRACT | FULL TEXT  

Building Multidimensional Biomarker Views of Type 2 Diabetes on the Basis of Protein Microheterogeneity
Borges et al.
Clin. Chem. 2011;57:719-728.
ABSTRACT | FULL TEXT  

Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
Loke et al.
BMJ 2011;342:d1309-d1309.
ABSTRACT | FULL TEXT  

Special considerations for treatment of type 2 diabetes mellitus in the elderly
Fravel et al.
Am J Health Syst Pharm 2011;68:500-509.
ABSTRACT | FULL TEXT  

What to add in with metformin in type 2 diabetes?
Petrie et al.
QJM 2011;104:185-192.
ABSTRACT | FULL TEXT  

How should we react to adverse drug reactions?
Ferner and Beard
Postgrad. Med. J. 2011;87:81-82.
FULL TEXT  

Analytical Issues Regarding Rosiglitazone Meta-analysis
Claggett and Wei
Arch Intern Med 2011;171:179-180.
FULL TEXT  

Analytical Issues Regarding Rosiglitazone Meta-analysis--Reply
Nissen and Wolski
Arch Intern Med 2011;171:180-180.
FULL TEXT  

Differential Effects of Rosiglitazone and Metformin on Postprandial Lipemia in Patients With HIV-Lipodystrophy
van Wijk et al.
Arterioscler. Thromb. Vasc. Bio. 2011;31:228-233.
ABSTRACT | FULL TEXT  

Estrogen Metabolomics: A Physiologist's Perspective
Miller
Hypertension 2010;56:816-818.
FULL TEXT  

Improving Drug Safety Surveillance: Lessons From Rosiglitazone
Masoudi
Circ Cardiovasc Qual Outcomes 2010;3:444-446.
FULL TEXT